leisure time -WSS

leisure time

author：knowledge 2025-09-28 19:25:31 - browse：362

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Researchers use wearables data and AI to predict preterm birth risk

leisure time

hotspot

WSS

Pennsylvania man bitten on the head by bear during attack in his garage

Why do women spend more than men on medical expenses?

Pennsylvania man bitten on the head by bear during attack in his garage

Did you have Obamacare on your GOP debate bingo card?

Medicare drug price negotiation program allowed for now

Kaiser Permanente unions announce official strike date

explore

leisure time

hotspot

Peter Hotez and the public health issue of online harassment

Address the ethical violations that led to 'Three Identical Strangers'

Continuity nursing helped my family in our darkest PICU moments

Flash flood warnings continue for parts of Missouri, Illinois

Activists slam private health insurers over coverage restrictions

Judge in Trump's classified documents case questions use of out

Virginia high school admissions case could be legal follow

Failure, not just success, should guide future doctors

Apple is now the first public company to be valued at $3 trillion

Sudafed saga points to U.S. issues with evaluating older drugs

leisure time

Kansas bar where gunfire wounded 9 last month closes permanently

Tuberculosis patients need more than just free medication

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

NFL doctors' conflicts of interest could endanger players, report says

WHO recommends dropping component of many flu vaccines

focus

leisure time

hotspot

leisure time